Physician profile
Lowell Weil
NPI 1942208558
$2,245,843.36
in general payments reported to CMS, 2019-2025
19 companies · $364K in 2025
The $364K reported for 2025 was more than what 99% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219K · 2020: $278K · 2021: $362K · 2022: $421K · 2023: $352K · 2024: $250K · 2025: $364K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $950K · Consulting Fee: $15K · Food and Beverage: $1,122 · Travel and Lodging: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $950,143.66 |
| Consulting Fee | $15,012.69 |
| Food and Beverage | $1,122.47 |
| Travel and Lodging | $327.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $1,445,363.08 | 2019-2025 | |
| Arthrex, INC. | $629,336.76 | 2019-2025 | Arthrex, Ar-8690s |
| Stryker Corporation | $141,921.50 | 2019-2025 | Anchorage, Nexfix, Bioskin |
| Ossio INC | $14,191.18 | 2024 | |
| Novastep INC. | $11,786.58 | 2020-2023 | Peca Bunion Correction System, Creed Ortholocent Implants, Apollo Ankle Fracture Plating System |
| Smith+Nephew, INC. | $1,475.00 | 2022 | |
| Medline Industries Lp | $350.80 | 2020-2025 | |
| Royal Biologics, INC. | $241.04 | 2020 | |
| Abbott Laboratories | $224.23 | 2022-2023 | Supera, Armada |
| Philips North America LLC | $203.82 | 2019 | |
| Alafair Biosciences, INC. | $177.25 | 2024 | Versawrap |
| Glw, INC | $172.49 | 2023 | Apollo Ankle |
| Bioventus LLC | $110.50 | 2024 | Exogen Ultrasound Bone Healing System |
| Organogenesis INC. | $93.39 | 2022 | |
| Orthofix Medical, INC. | $66.87 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $60.66 | 2019 | |
| Melinta Therapeutics, LLC | $44.68 | 2019 | |
| Cordis US Corp. | $23.53 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lowell Weil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.